Clinical Trials
Currently Active (recruiting)
SNB-101 – ES-SCLC(NCT07391813)
The Phase 1b/2 Study (SNB-101-101) is a multi-center, multi-cohort, open-label study designed to evaluate the safety, tolerability, and efficacy of SNB-101 in up to 55 patients with extensive-stage small cell lung cancer (ES-SCLC). The Phase 1b aims to determine the maximum tolerated dose (MTD) and further clarify the pharmacokinetics (PK) of the drug, In Phase 2, participants will be randomized 1:1 into two cohorts (20 patients per cohort) to determine the optimal dose for future research while collecting additional data on safety and clinical outcomes. Eligible participants receive SNB-101 via intravenous infusion on Day 1 and Day 15 of each 28-day treatment cycle. Detailed information regarding this study may be found on clinicaltrials.gov under trial identifier
NCT07391813.
Completed
SNB-101 – Solid Tumor(NCT04640480)
The Phase 1 Study (SNB101P01) is a accelerated dose finding study with 21 solid tumor patients who had progression after prior standard of care treatment, and we assessed safety, tolerability, and pharmacokinetics of drug. All participants received SNB 101 in different cohorts, from 5 to 50 mg/m2 as SN-38. SNB 101 was administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. More information about SNB101P01 may be found on clinicaltrials.gov under trial identifier NCT04640480.
SNA-001(PANCRAXEL®) – Pancreatic Cancer
SNA-001 is anti-cancer drug for pancreatic, breast and non-small cell lung cancer. It adopted albumin nanoparticle drug delivery system to improve safety and efficacy of Taxol® (paclitaxel) that has been used for various solid tumors, especially for breast cancer. We will recruit patients for phase 1 study in South Korea, and will assess pharmacokinetic profile, safety and efficacy of SNA-001.